The median event-free survival was 3 months in both treatment arms.
The combination of ivosidenib plus azacitidine significantly prolonged OS with a median of 24.0 months compared with 7.9 months with placebo plus azacitidine.
The underlying mechanisms of late recurrence must be investigated further, according to researchers.
Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.
Researchers analyzed treatment trends and outcomes over time to identify the optimal management strategy for TP53-mutated AML.
The median duration of response was not reached in patients with follicular lymphoma or diffuse large B-cell lymphoma.
Predictors of worse progression-free survival included ISS stage II, ISS stage III, and adverse cytogenetics.
Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.
Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Researchers sought to determine whether a low dose of inotuzumab ozogamicin would be safe and effective in patients with relapsed/refractory ALL.
Researchers sought to determine whether there are disparities by race/ethnicity and socioeconomic status in survival outcomes of children with ALL.
Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.
Researchers sought to determine whether lisocabtagene maraleucel would improve outcomes compared with standard of care in second-line therapy in patients with LBCL.
A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.
The study included 203 patients with steroid-resistant acute GVHD who were treated at 10 centers in China between September 2014 and March 2019.
Factors associated with an increased risk of death were older age, male sex, a pre-COVID-19 prognosis of 6 months or less, and deferring ICU care.
Circulating tumor DNA status before and during treatment predicted progression-free and overall survival.
Axicabtagene ciloleucel improved responses and prolonged event-free survival.
The UKALL 2003 trial randomly assigned patients to a standard or augmented regimen post remission therapy according to their MRD stratification.